Across TCGA pan-cancer cohorts, ZNF679 Mutation is linked to patient survival in 9 of 34 cancer types, making it a survival-associated ZNF679 data layer compared with 20 for mass-spec protein.
The strongest signal is observed in mesothelioma (MESO), where higher ZNF679 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated ZNF679 expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.
MESO, SARC, and COAD are the cancer types where ZNF679 Mutation most reproducibly stratifies survival.
Mutation survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.